- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00471939
Safety and Efficacy of I-020502 in Meshed Skin Autografting
March 2, 2009 updated by: Kuros Biosurgery AG
A Phase II, Multi-Centre, Controlled Study of the Safety and Efficacy of Wound Healing Gel I-020502 (KUR-212) in Patients Undergoing Autologous Meshed Skin Grafting.
This is a phase II, multi-centre, controlled study comparing the safety and tolerability on wound healing following an application of I-020502 in a concentration of 1μg/mL TG-PDGF.AB versus staples applied in the same patient to burn areas requiring autologous meshed skin grafting.
Study Overview
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bochum, Germany, 44789
- Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent by the patient or his/her legal representative.
- Male or female, aged ≥ 18 years.
- Female with childbearing potential with a negative pregnancy test within 3 day prior to surgery (screening).
- Patients with burn wound(s) between ≥ 5 % and ≤ 50 % TBSA.
- Patients with a contiguous deep partial thickness/full thickness wound(s) of two comparable sites either contiguous or separate in the same location (e.g. leg) each sized between 1% and 2% TBSA but not more than 400 cm2.
- Patients who are willing to comply with treatment applications and instructions by the protocol.
Exclusion Criteria:
- Females who are pregnant or breast-feeding.
- Patients with known or suspected allergies to any of the components of the wound healing gel I-020502 (e.g. hypersensitivity to bovine proteins).
- Digits, head, genitalia, palms of hands, soles of feet, and face are excluded as test sites.
- Electrical and/or chemical burns.
- Patients that are judged to have significant pulmonary compromise.
- Transcutaneous tissue oxygenation < 90%.
- Clinically significant infections at wound sites.
- Clinically significant systemic infections.
- Suspicion or presence of active systemic or local cancer or tumor of any kind.
- Patients with known immunodeficiency disorders, either congenital or acquired.
- Patients with vascular or skin disorders that directly affect the designated wound site.
- Patients with Diabetes mellitus.
- Patients with chronic malnourishment.
- Chronic treatment with immunosuppressive drugs or systemic corticosteroids within the last 2 months prior to surgery.
- Any other acute or chronic concurrent medical conditions that in the Investigator's opinion are a contraindication to skin mesh grafting and study participation.
- Participation in another investigational study within 30 days prior to surgery, for investigational devices, or within the last three months for investigational drugs related to wound healing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of treatment-related adverse events up to 28 days post surgery
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of AE/SAE, Changes in vital signs, Hematology/clinical chemistry, PDGF.AB/TG-PDGF.AB and antibodies, hypergranulation, Percentage and proportion of re-epithelialization/engraftment, Scar assessment, Time and resources for test site treatments
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Marcus Lehnhardt, Dr., Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
January 1, 2009
Study Registration Dates
First Submitted
May 9, 2007
First Submitted That Met QC Criteria
May 9, 2007
First Posted (Estimate)
May 10, 2007
Study Record Updates
Last Update Posted (Estimate)
March 3, 2009
Last Update Submitted That Met QC Criteria
March 2, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Other Study ID Numbers
- CS I-020502/01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
Virginia Commonwealth UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
St. Justine's HospitalRecruiting
Clinical Trials on I-020502
-
Hero Institute for Infant NutritionUniversidad de Murcia; University of Valencia; Universidad de GranadaCompletedConditions Influencing Health StatusSpain
-
VA Office of Research and DevelopmentActive, not recruitingInsomnia | Traumatic Brain InjuryUnited States
-
University of California, Los AngelesCompletedInsomnia ChronicUnited States
-
Helsinki University Central HospitalUniversity of Helsinki; Finnish Institute for Health and Welfare; Finnish Institute...RecruitingSchizophrenia | Schizoaffective Disorder | InsomniaFinland
-
Nottingham University Hospitals NHS TrustWellcome TrustCompleted
-
University of WuerzburgDeutsche Krebshilfe e.V., Bonn (Germany)RecruitingDifferentiated Thyroid CarcinomaGermany
-
Haukeland University HospitalUppsala University; University of Bergen; University of AgderCompletedLymphoma | Breast Cancer | Colorectal Cancer | Prostate Cancer | Testicle CancerNorway
-
Florida International UniversityAndrew Kukes Foundation for Social AnxietyCompleted
-
Chinese University of Hong KongNot yet recruitingAdolescent | Depression | InsomniaHong Kong
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...RecruitingFoot Diseases | Complex Regional Pain Syndromes | Pain, Joint | Ankle DiseaseItaly